BioLite Japan

BioLite is a clinical-stage biotechnology company specializing in the development of novel therapeutics for central nervous system (CNS) disorders and oncology. Headquartered in Taiwan with a significant operational presence in Japan through BioLite Japan K.K., the company focuses on transforming botanical extracts into standardized, high-purity pharmaceutical products. Its lead program, BLI-1005, is a non-stimulant treatment for Attention Deficit Hyperactivity Disorder (ADHD) that has demonstrated promising results in Phase 2 clinical trials. BioLite's pipeline also includes candidates for major depressive disorder and opioid withdrawal, utilizing a rigorous scientific approach to validate traditional medicine components. The company aims to provide safer alternatives to current stimulant-based therapies by leveraging its proprietary botanical drug development platform. BioLite Japan K.K. plays a crucial role in managing clinical trials and regulatory submissions within the Japanese and broader Asian markets.